LBA
CADL icon

Letko, Brosseau & Associates’s Candel Therapeutics CADL Stock Holding History

Letko, Brosseau & Associates’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
+25,050
New +$189K ﹤0.01% 98

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Letko, Brosseau & Associates's CADL Position: Q2 2026 in Review

Letko, Brosseau & Associates opened a new position in Candel Therapeutics (CADL) in Q2 2026: 25,050 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #98 among its holdings.

138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Letko, Brosseau & Associates held 25,050 shares of Candel Therapeutics worth $258K as of Q2 2026.
  • Candel Therapeutics was a new Letko, Brosseau & Associates position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #98 holding.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.